Autolus Therapeutics plc
AUTL
$2.03
-$0.08-3.79%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 118.37% | 191.89% | 83,655.17% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.37% | 191.89% | 83,655.17% | -- | -- |
| Cost of Revenue | -6.76% | 2.45% | 62.47% | 40.21% | 4,849.90% |
| Gross Profit | 91.35% | 45.21% | 10.14% | 12.36% | -2,853.44% |
| SG&A Expenses | 36.00% | 35.26% | -1.36% | 32.75% | 38.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.99% | 15.51% | 26.66% | 37.19% | 40.37% |
| Operating Income | 28.39% | 8.78% | 5.21% | -5.87% | -4.62% |
| Income Before Tax | 18.67% | -4.12% | -250.04% | 4.25% | 18.38% |
| Income Tax Expenses | 17.13% | -61.21% | -180.92% | 2,318.18% | 678.43% |
| Earnings from Continuing Operations | 18.38% | -2.05% | -227.22% | 3.63% | 17.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.38% | -2.05% | -227.22% | 3.63% | 17.77% |
| EBIT | 28.39% | 8.78% | 5.21% | -5.87% | -4.62% |
| EBITDA | 30.01% | 9.77% | 6.11% | -5.13% | -3.94% |
| EPS Basic | 18.39% | -2.05% | -227.29% | 3.63% | 17.81% |
| Normalized Basic EPS | 18.73% | -4.14% | -245.88% | 4.06% | 17.82% |
| EPS Diluted | 18.39% | -2.05% | -227.29% | 3.63% | 17.81% |
| Normalized Diluted EPS | 18.73% | -4.14% | -245.88% | 4.06% | 17.82% |
| Average Basic Shares Outstanding | 0.01% | 0.01% | -0.02% | 0.02% | 0.04% |
| Average Diluted Shares Outstanding | 0.01% | 0.01% | -0.02% | 0.02% | 0.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |